Koskela K, Pelliniemi T T, Remes K, Rajamäki A, Pulkki K
Department of Medicine, Turku University Central Hospital, Finland.
Br J Haematol. 1997 Jan;96(1):158-60. doi: 10.1046/j.1365-2141.1997.8522478.x.
The serum concentration of oncostatin M (OSM) was measured in 40 multiple myeloma patients at diagnosis. Serum OSM level exceeded the sensitivity limit of the ELISA assay in eight (20%) of these patients (OSM+ patients). The serum levels of IL-6, another member of the gp180 cytokine family and C-reactive protein (CRP) as a surrogate of IL-6 were significantly higher in OSM+ patients. There was a trend towards higher serum beta 2M concentration in OSM+ patients, whereas there was no difference in the serum sIL-6R level or clinical data (age, gender, myeloma protein or stage) between the two groups. Two human myeloma cell lines secreted OSM and IL-6, but not IL-11 or leukaemia inhibitory factor (LIF), which suggests an important role for OSM and IL-6 in supporting growth of myeloma cells.
在40例多发性骨髓瘤患者确诊时测定了抑瘤素M（OSM）的血清浓度。这些患者中有8例（20%）的血清OSM水平超过了ELISA检测的灵敏度极限（OSM+患者）。OSM+患者中，gp180细胞因子家族的另一个成员IL-6以及作为IL-6替代指标的C反应蛋白（CRP）的血清水平显著更高。OSM+患者的血清β2M浓度有升高趋势，而两组之间血清sIL-6R水平或临床数据（年龄、性别、骨髓瘤蛋白或分期）无差异。两种人骨髓瘤细胞系分泌OSM和IL-6，但不分泌IL-11或白血病抑制因子（LIF），这表明OSM和IL-6在支持骨髓瘤细胞生长中起重要作用。
